China NMPA Medical Device Registration Service

Scope and evidence must be confirmed before any paid tests or filings.

China NMPA medical device registration service is the execution of a defined device filing: confirm the Chinese classification and origin, appoint the correct applicant and agent, reconcile the technical evidence, submit to the competent authority and manage questions, certificates and changes. Registration and Class I filing are distinct procedures. A CE mark or a foreign approval alone does not establish the correct Chinese filing route.

Choose the filing route before preparing the dossier

Select by Chinese device class and by whether the device is imported or manufactured domestically. This is a procedural routing table, not an opinion that a particular device qualifies for a class.

Device and route	Competent authority and resulting record
Imported Class I	File with NMPA; obtain a filing number, not a Class II/III registration certificate.
Imported Class II or III	Submit a registration application to NMPA; technical evaluation of these products is performed by CMDE.
Domestic Class I or II	Class I: file with the drug regulator of a city divided into districts. Class II: obtain registration from the provincial drug regulator.
Domestic Class III	Apply for product registration with NMPA; CMDE carries out technical evaluation.

For domestically manufactured Class I devices, filing must be completed before manufacturing. In-vitro diagnostic reagents regulated as medical devices follow separate IVD registration/filing provisions. Determine the classification, intended use and manufacturing origin before treating a route as final.

Who prepares, owns and submits the application

The registration service coordinates the hand-offs, but cannot replace the applicant’s underlying legal and technical responsibilities.

Responsible participant	Evidence and action owned
Registrant or filing entity	Controls product identity, claims, design history, test data, quality system and truthful dossier; approves final submission and post-market obligations.
China agent for an overseas applicant	Must be an enterprise legal person established in China; facilitates filing and communications and assists the overseas registrant with statutory duties. The overseas registrant remains accountable.
Regulatory submission team	Maintains a version-controlled Chinese dossier, aligns names and models across documents, routes questions to technical owners and records every regulator response.

Dossier release checklist: what must match

For Class II/III registration, assemble the following evidence and cross-check each item against the intended use, model list, product technical requirements (PTR) and labeling:

Chinese application documents, with original foreign-language documents alongside translations; consistent applicant and manufacturing-site identifiers.
Medical-device description, product variants, classification rationale and intended-use statements that do not conflict with the instructions for use (IFU).
Product risk analysis, non-clinical safety/performance data and a traceable mapping from hazards to verification evidence.
PTR and corresponding product test report; the law can permit qualifying applicant self-test reports or reports from qualified commissioned institutions.
Clinical evaluation materials or a documented basis for an applicable exemption; a clinical trial is not automatic for every product.
IFU and label samples, quality management system information for product development/manufacturing and evidence of traceable production.
For imported products, the required home-market marketing proof or a properly supported applicable exception for certain innovative products.

This is an execution checklist, not a replacement for the current NMPA dossier format or product-specific standards. Class I filing materials are assessed under the applicable filing requirements rather than copied mechanically from Class II/III registration.

Six operational steps from readiness to decision

Freeze the product scope: confirm Chinese classification, whether it is an IVD, origin, intended use, variants and competent authority.
Appoint and verify the applicant and, for an overseas applicant, its China-based legal-person agent; document authorizations and communication ownership.
Complete risk, PTR, testing, clinical-route and QMS evidence; reconcile terminology, versions, IFU and Chinese/original source documents.
Make the appropriate filing or submit the Class II/III registration online when study evidence is complete and the QMS is inspection-ready; monitor acceptance and any payment notice.
During technical evaluation, resolve requests and possible QMS inspections. A formal supplementation notice under Article 54 requires all requested materials in one complete submission within one year of receipt. If the deadline is missed, technical evaluation is terminated and the registration application is rejected.
After filing or a registration decision, archive the Class I filing information or the Class II/III registration certificate and its approved technical requirements; assign owners for label controls, change review and renewal.

A fixed approval duration or universal official fee cannot be promised without the specific product route and current NMPA fee schedule. Filing acceptance, technical review and administrative approval are different checkpoints.

Delay and rejection triggers to test before filing

Use the following failure-to-action checks before the submission is released:

Wrong class/origin or IVD route → stop submission and verify the applicable Chinese classification and authority.
PTR, test report, IFU and device models contradict each other → reconcile scope and repeat any necessary verification before filing.
Missing home-market marketing document, weak clinical justification or unsupported exemption → document the precise lawful basis and supply traceable evidence.
Incomplete Chinese translations, unsupported claims, failed QMS inspection or fragmented supplementation response → repair the source dossier and coordinate one complete response.

Ongoing obligations after filing or registration

Class II/III registration certificates normally remain valid for five years; submit a renewal application six months before expiry, checking intervening mandatory standards and any certificate conditions.
Substantial changes to design, raw materials, manufacturing process or intended use that may affect safety or effectiveness require change registration with the original registration authority; certain other recorded changes must be filed with that authority within 30 days from the date of change. Classify each change before implementation.
For Class I filings, update filed information and product technical requirements through the relevant change-filing procedure when applicable; a move to Class II/III requires registration.
Continue the quality-management, risk, surveillance and product-record duties of the registrant; an issued number or certificate is not a blanket approval for different products or claims.

What this service does not duplicate

If the main problem is choosing a clinical or regulatory strategy rather than executing a settled filing, use NMPA registration advisory service; if the main problem is selecting and contracting the domestic legal-person representative, use China local-agent service.

Official regulatory sources

Practical questions

Does a Class I device need clinical evaluation materials?: The NMPA 2021 implementation notice says no clinical evaluation data is submitted for Class I filing. The device must genuinely qualify as Class I, and the other filing evidence remains necessary.
Can a foreign manufacturer submit without a Chinese agent?: No: an overseas applicant or filer must designate an enterprise legal person in China as agent. The arrangement assists filing; it does not transfer the overseas registrant’s legal responsibilities.
Is proof of home-country marketing always required?: It is generally required for imported registration/filing. Decree 47 provides a conditional exception for certain innovative devices not marketed in the relevant home jurisdiction; verify facts and evidence before relying on it.
Must all product testing be carried out by a Chinese laboratory?: Do not assume so. Decree 47 permits self-test reports or reports from qualified commissioned medical-device testing institutions, subject to device-specific technical conditions and required testing evidence.
What if CMDE asks for supplementary materials?: Read the formal notice and respond as a coordinated complete package. Under Decree 47 Article 54, submit the required supplements in one delivery within one year after receiving the notice; failure to do so terminates technical evaluation and results in rejection of the registration application.